Human thioredoxin reductase is efficiently inhibited by (2,2′:6′,2′-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy

Journal of Medicinal Chemistry

Volumn 44, Issue 17, 2001, Pages 2784-2792

  Becker, K ^a   Herold Mende, C ^b   Park, J J ^c   Lowe, G ^c   Heiner Schirmer, R ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(2,2':6',2'' TERPYRIDINE)PLATINUM; LOMUSTINE; NITROSOUREA DERIVATIVE; PLATINUM COMPLEX; PROCARBAZINE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; COMPETITIVE INHIBITION; COMPLEX FORMATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; OXIDATION REDUCTION REACTION; PROTEIN LOCALIZATION; STOICHIOMETRY; SURVIVAL TIME;

2,2'-DIPYRIDYL; ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; ORGANOPLATINUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOREDOXIN REDUCTASE (NADPH); TUMOR CELLS, CULTURED;

EID: 0035899183     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm001014i     Document Type: Article

References (57)

1. Lipoamide dehydrogenase, glutathione reductase, thioredoxin reductase mercuric ion reductase a family of flavoenzyme transhydrogenases
2. Substitution of the thioredoxin system for glutathione reductase
3. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue
4. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli
5. Thioredoxin reductase as a pathophysiological factor and drug target
6. Thioredoxin reductase
7. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases
8. Redox regulation by the thioredoxin glutaredoxin system
9. Disulfidereductase inhibitors as chemotherapeutic agents: The design of drugs for trypanosomiasis and malaria
10. A new selenoprotein from human lung adenocarcinoma cells: Purification, properties, and thioredoxin reductase activity
11. Contrasting patterns of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase
12. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway
13. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells
14. The thioredoxin/thioredoxin reductase redox system and control of cell growth
15. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): Thioredoxin mRNA is elevated in some human tumors
16. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I-Epstein-Barr virus-transformed lymphocytes. Acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2
17. 1,3-Bis(2-chloroethyl)-1-nitrosourea as thiol-carbamoylating agent in biological systems
18. The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase
19. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds
20. The basis for current treatment recommendations for malignant gliomas
21. Prognosis of brain tumors: Epidemiology, survival time clinical course
22. Epidemiological study of primary intracranial tumors: A regional survey in kumamoto prefecture in the southern part of Japan
23. Epidemiological study of primary intracranial tumours in elderly people
24. Primary tumors of the brain cranial nerves and cranial meninges in Victoria, Australia, 1982-1990 patterns of incidence and survival
25. Epidemiology of brain tumors: The national survey of intracranial neoplasms
26. Patient age, histologic features length of survival in patients with glioblastoma multiforme
27. Indications for surgery in the management of gliomas
28. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant gliomas
29. Practical guidelines for the treatment of malignant gliomas
30. Malignant glioma who benefits from adjuvant chemotherapy?
31. Current status of platinum-based antitumor drugs
32. Metallointercalation reagents. 2-Hydroxyethanethiolato(2,2′2,′terpyridine)-platinum(II) monocation binds strongly to D.N.A. by intercalation
33. 4-Picoline-2,2′6′2″-terpyridine-platinum(II)-a potent intercalator of DNA
34. Cytotoxicity of (2,2′,6′,2″-terpyridine)platinum(II) complexes to Leishmenia donovani, Trypanosoma cruzi, and Trypanosoma brucei
35. Cytotoxicity of (2,2′6′2″-terpyridine)platinum(II) complexes against human ovarian carcinoma
36. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell?
37. Protective activity of adult T. Cell leukemiaderived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells
38. NK-lysin, a novel effector peptide of cytotxic T and NK cells. Structure and cDNA cloning of the porcine form, induction by interleukin 2, antibacterial antitumour activity
39. NK-lysin, a disulfidecontaining effector peptide of T-lymphocytes, is reduced inactivated by human thioredoxin reductase. Implication for a protective mechanism against NK-lysin cytotoxicity
40. The mechanism of action of the nitrosourea antitumor drugs on thioredoxin reductase, glutathione reductase ribonucleotide reductase
41. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine
42. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II)
43. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide
44. Redox regulation of transcriptional activators
45. Role of cysteine residues in regulation of P53 function
46. Thioredoxin regulates the DNA binding activity of NFkappa B by reduction of a disulphide bond involving cysteine 62
47. Mutation in a thioredoxin reductase homologue suppresses p53-induced growth inhibition in the fission yeast Schizosaccharomyces pombe
48. Autoantibody to thioredoxin reductase in an ovarian cancer patient
49. Aurothioglucose inhibits murine thioredoxin reductase activity in vivo
50. Inhibition of human glutathione reductase by the nitrosourea drugs 1,3-bis(2-chloroethyl)-1-nitrosourea 1-(2chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea. A. crystallographic analysis
51. Synthesis of 5,5′-dithiobis(2-nitrobenzamides) as alternative substrates for trypanothione reductase andthioredoxin reductase a microtiter colorimetric assay for inhibitor screening
52. Folding of the four domains and dimerization are impaired by the Gly446 → Glu exchange in human glutathione reductase. Implications for the design of antiparasitic drugs
53. Thioredoxin and thloredoxin thioredoxin reductase
54. An improved method for the synthesis of (2,2′,6′,2″-terpyridine)platinum(II) complexes
55. (2,2′,6′,2″-terpyridine platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase
56. Autocrine growth regulation by granulocyte colony-stimulating factor granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression